Abstract
Introduction: To date, almost 7 billion doses of the different types of vaccine against SARS-CoV-2 have been administered worldwide. Although the severity of new cases of SARS-CoV-2 has progressively decreased, and the pressure on national health systems has declined, the development of de novo glomerular injuries has been suggested. Methods: This study aimed to examine the patients who were hospitalized in our Unit between April and November 2021 and underwent renal biopsy for new-onset urinary abnormalities (UA) and/or renal impairment within 3 months of SARS-CoV-2 vaccination. Results: We identified 17 patients who developed UA and/or renal insufficiency within 3 months of vaccination. Minimal change disease was the most common disease in our cohort (5 patients, 29.4%) followed by acute tubulointerstitial nephritis (TIN; 3 patients, 17.6%), membranous nephropathy (3 patients, 17.6%), and rapidly progressive IgA nephropathy (2 patients, 11.8%). The other 4 patients had a diagnosis of membranoproliferative glomerulonephritis (1 patient), systemic lupus erythematosus (1 patient), ANCA-associated vasculitis (1 patient), and tip-variant focal segmental glomerulosclerosis (1 patient), respectively. Eight out of the 17 patients (47.1%) developed acute kidney injury. Two patients with acute TIN had to start hemodialysis that was discontinued after 1 and 2 months, respectively, due to the recovery of renal function. All patients underwent treatment with corticosteroids and/or immunosuppressants. Discussion: Although it is not possible to conclusively determine whether there is a causal relationship between SARS-CoV-2 vaccination and new-onset nephropathies, based on the appearance of UA and/or renal insufficiency shortly after vaccination, we hypothesize that the immune response to the COVID-19 vaccine may be a trigger of nephropathies. Therefore, our results highlight the need for pharmacovigilance. However, this report should not lead to vaccine hesitation during this pandemic as the benefits of vaccination strongly outweigh the potential risks.
Journal Section:
Editor's choice
References
1.
Li
NL
, Coates
PT
, Rovin
BH
. COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation
. Kidney Int
. 2021 Nov
;100
(5
):959
–65
.2.
Gutiérrez
S
, Dotto
B
, Petiti
JP
, De Paul
AL
, Dionisio de Cabalier
ME
, Torres
AI
, . Minimal change disease following influenza vaccination and acute renal failure: just a coincidence
. Nefrologia
. 2012 May
;32
(3
):414
–5
.3.
Kikuchi
Y
, Imakiire
T
, Hyodo
T
, Higashi
K
, Henmi
N
, Suzuki
S
, . Minimal change nephrotic syndrome, lymphadenopathy and hyperimmunoglobulinemia after immunization with a pneumococcal vaccine
. Clin Nephrol
. 2002 Jul
;58
(1
):68
–72
.4.
Ozdemir
S
, Bakkaloğlu
A
, Oran
O
. Nephrotic syndrome associated with recombinant hepatitis B vaccination: a causal relationship or just a mere association
. Nephrol Dial Transplant
. 1998 Jul
;13
(7
):1888
–9
.5.
Clajus
C
, Spiegel
J
, Bröcker
V
, Chatzikyrkou
C
, Kielstein
JT
. Minimal change nephrotic syndrome in an 82 year old patient following a tetanus-diphteria-poliomyelitis-vaccination
. BMC Nephrol
. 2009 Aug
;10
:21
.6.
Heymann
F
, Meyer-Schwesinger
C
, Hamilton-Williams
EE
, Hammerich
L
, Panzer
U
, Kaden
S
, . Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury
. J Clin Invest
. 2009 May
;119
(5
):1286
–97
.7.
Topaloğlu
R
, Saatçi
U
, Arikan
M
, Canpinar
H
, Bakkaloğlu
A
, Kansu
E
. T-cell subsets, interleukin-2 receptor expression and production of interleukin-2 in minimal change nephrotic syndrome
. Pediatr Nephrol
. 1994 Dec
;8
(6
):649
–52
.8.
Mancianti
N
, Guarnieri
A
, Tripodi
S
, Salvo
DP
, Garosi
G
. Minimal change disease following vaccination for SARS-CoV-2
. J Nephrol
. 2021 Aug
;34
(4
):1039
–40
.9.
Weijers
J
, Alvarez
C
, Hermans
MMH
. Post-vaccinal minimal change disease
. Kidney Int
. 2021 Aug
;100
(2
):459
–61
.10.
De la Flor
J
, Linares
T
, Alonso-Riaño
M
, Segura
P
, Albarracin
C
, Ruiz
E
, . A case of acute interstitial nephritis following the Pfizer-BioNTech COVID-19 vaccine
. Nefrologia
. 2021 Jun
. Epub ahead of print.11.
Dheir
H
, Sipahi
S
, Cakar
GC
, Yaylaci
S
, Hacibekiroglu
T
, Karabay
O
. Acute tubulointerstitial nephritis after COVID-19 m-RNA BNT162b2 vaccine
. Eur Rev Med Pharmacol Sci
. 2021 Oct
;25
(20
):6171
–3
.12.
Sahin
U
, Muik
A
, Derhovanessian
E
, Vogler
I
, Kranz
LM
, Vormehr
M
, . COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
. Nature
. 2020 Oct
;586
(7830
):594
–9
.13.
Mendonça
SA
, Lorincz
R
, Boucher
P
, Curiel
DT
. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
. NPJ Vaccines
. 2021 Aug
;6
(1
):9
.14.
Lebedev
L
, Sapojnikov
M
, Wechsler
A
, Varadi-Levi
R
, Zamir
D
, Tobar
A
, . Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine
. Am J Kidney Dis
. 2021 Jul
;78
(1
):142
–5
.15.
Thappy
S
, Thalappil
SR
, Abbarh
S
, Al-Mashdali
A
, Akhtar
M
, Alkadi
MM
. Minimal change disease following the Moderna COVID-19 vaccine: first case report
. BMC Nephrol
. 2021 Nov
;22
(1
):376
.16.
Hanna
J
, Ingram
A
, Shao
T
. Minimal change disease after first dose of Pfizer-BioNTech COVID-19 vaccine: a case report and review of minimal change disease related to COVID-19 vaccine
. Can J Kidney Health Dis
. 2021 Nov
;8
:20543581211058271
.17.
Komaba
H
, Wada
T
, Fukagawa
M
. Relapse of minimal change disease following the Pfizer-BioNTech COVID-19 vaccine
. Am J Kidney Dis
. 2021 Sept
;78
(3
):469
–70
.18.
D’Agati
VD
, Kudose
S
, Bomback
AS
, Adamidis
A
, Tartini
A
. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine
. Kidney Int
. 2021 Aug
;100
(2
):461
–3
.19.
Baskaran
K
, Cohen
AWS
, Weerasinghe
N
, Vilayur
E
. Report of two cases of minimal change disease following vaccination for COVID-19
. Nephrology
. 2022 Jan
;27
(1
):111
–2
.20.
Maas
RJ
, Gianotten
S
, Van der Meijden
WAG
. An additional case of minimal change disease following the Pfizer-BioNTech COVID-19 vaccine
. Am J Kidney Dis
. 2021 Aug
;78
(2
):312
.21.
Kervella
D
, Jacquemont
L
, Chapelet-Debout
A
, Deltombe
C
, Ville
S
. Minimal change disease relapse following SARS-CoV-2 mRNA vaccine
. Kidney Int
. 2021 Aug
;100
(2
):457
–8
.22.
Liu
F
, Feng
C
, Mao
J
, Fu
H
. New-onset and relapsing glomerular diseases related to COVID-19 vaccination
. Zhejiang Da Xue Xue Bao Yi Xue Ban
. 2021 Aug
;50
(4
):524
–8
.23.
Klomjit
N
, Alexander
MP
, Fervenza
FC
, Zoghby
Z
, Garg
A
, Hogan
MC
, . COVID-19 vaccination and glomerulonephritis
. Kidney Int Rep
. 2021 Dec
;6
(12
):2969
–78
.24.
Plasse
R
, Nee
R
, Gao
S
, Olson
S
. Acute kidney injury with gross hematuria and IgA nephropathy after COVID-19 vaccination
. Kidney Int
. 2021 Oct
;100
(4
):944
–5
.25.
Abramson
M
, Mon-Wei Yu
S
, Campbell
KN
, Chung
M
, Salem
F
. IgA nephropathy after SARS-CoV-2 vaccination
. Kidney Med
. 2021 Sep–Oct
;3
(5
):860
–3
.26.
Niel
O
, Florescu
C
. IgA nephropathy presenting as rapidly progressive glomerulonephritis following first dose of COVID-19 vaccine
. Pediatr Nephrol
. 2021 Nov
;16
:1
–2
.27.
Gueguen
L
, Loheac
C
, Saidani
N
, Khatchatourian
L
. Membranous nephropathy following anti-COVID-19 mRNA vaccination
. Kidney Int
. 2021
;100
(5
):1140
–1
.28.
Da
Y
, Goh
GH
, Khatri
P
. A case of membranous nephropathy following Pfizer-BioNTech mRNA vaccination against COVID-19
. Kidney Int
. 2021 Oct
;100
(4
):938
–9
.29.
Shakoor
MT
, Birkenbach
MP
, Lynch
M
. ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine
. Am J Kidney Dis
. 2021 Oct
;78
(4
):611
–3
.30.
Missoum
S
, Lahmar
M
, Khellaf
G
. Leukocytoclastic vasculitis and acute renal failure following inactivated SARS-CoV-2 vaccine
. Nephrol Ther
. 2021 Dec 8
. Epub ahead of print.31.
Liew
SK
, Nair
B
, So
B
, Ponnusamy
A
, Bow
A
, Woywodt
A
. Acute interstitial nephritis following SARS-CoV-2 virus vaccination
. Clin Nephrol
. 2022 Feb 3
. Epub ahead of print. http://dx.doi.org/10.5414/CN110753.32.
Kielstein
JT
, Termühlen
L
, Sohn
J
, Kliem
V
. Minimal change nephrotic syndrome in a 65-year-old patient following influenza vaccination
. Clin Nephrol
. 2000 Sept
;54
(3
):246
–8
.33.
Neves
PD
, Caires
RA
, Guimarães
MP
, Costalonga
EC
, Cavalcante
LB
, Costa E Silva
VT
, . Collapsing glomerulopathy following SARS-CoV-2 adenovirus-vector-based vaccine: report of 2 cases
. Kidney Int
. 2022 Jan 4
;101
(3
):637
–9
.34.
Jefferis
J
, Kassianos
AJ
, Grivei
A
, Doucet
B
, Healy
H
, Francis
L
, . SARS-CoV-2 vaccination-associated collapsing glomerulopathy in a kidney transplant recipient
. Kidney Int
. 2022 Jan 4
;101
(3
):635
–6
.35.
Bomback
AS
, Kudose
S
, D’Agati
VD
. De novo and relapsing glomerular diseases after COVID-19 vaccination: what do we know so far
. Am J Kidney Dis
. 2021 Oct
;78
(4
):477
–80
.36.
Uppal
NN
, Kello
N
, Shah
HH
, Kanhin
Y
, Ramirez de Oleo
I
, Epstein
E
, . De novo ANCA-associated vasculitis with glomerulonephritis in COVID-19
. Kidney Int Rep
. 2020 Nov
;5
(11
):2079
–83
.37.
Shetty
AA
, Tawhari
I
, Safar-Boueri
L
, Seif
N
, Alahmadi
A
, Gargiulo
R
, . COVID-19-associated glomerular disease
. J Am Soc Nephrol
. 2021 Jan
;32
(1
):33
–40
.38.
Gupta
RK
, Bhargava
R
, Shaukat
AA
, Albert
E
, Leggat
J
. Spectrum of podocytopathies in new-onset nephrotic syndrome following COVID-19 disease: a report of 2 cases
. BMC Nephrol
. 2020 Aug
;21
(1
):326
.39.
Xu
S
, Yang
K
, Li
R
, Zhang
L
. mRNA vaccine era-mechanisms, drug platform and clinical prospection
. Int J Mol Sci
. 2020 Sept
;21
(18
):6582
.40.
Vivarelli
M
, Massella
L
, Ruggiero
B
, Emma
F
. Minimal change disease
. Clin J Am Soc Nephrol
. 2017
;12
(2
):332
–45
.41.
Vojdani
A
, Vojdani
E
, Kharrazian
D
. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases
. Front Immunol
. 2021 Jan
;11
:617089
.© 2022 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2022
You do not currently have access to this content.
